Cardiothoracic & vascular anesthesia
Postoperative hemodynamic stability of patients treated with the sacubritil-valsartan combination in cardiac surgery
Authors' conclusion
In this exploratory study in cardiac surgery, preoperative treatment with SVC was not associated with increased vasoplegia and vasoactive drug consumption.
Study context
- Population
- Patients undergoing elective cardiac surgery, January 2022 to March 2024matched cohort
- Participants
- 28 vs 56
- Exposure
- Preoperative Sacubitril-Valsartan combination (SVC) treatment vs no SVC exposure
- Exposedn = 28
- Non-exposedn = 56reference
- Outcome
- Vasoactive-Inotropic Score (VIS)
- Follow-up
- First 24 h postoperatively
Methodological detailssingle-centre, propensity-score matched (1:2), exploratory
- Single-centre
- Propensity-score matched (1:2)
- Exploratory
Main finding
As reported in the abstract
Exposed
21.5
± 15
Non-exposed
21.4
± 18
P = 0.86
Observational data: associations, not effects.
Further findings
Vasoactive-Inotropic Score (VIS) during first 5 days, norepinephrine and dobutamine duration, lactate change, vascular filling, fluid balance, mechanical ventilation duration, ICU LOS
- No significant difference
Off-pump coronary artery bypass surgery (subgroup)
- Results similar
Safety
Acute renal failure
- No significant difference
Original publication
Postoperative hemodynamic stability of patients treated with the sacubritil-valsartan combination in cardiac surgery. Anaesth Crit Care Pain Med. Published 26 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →